A response letter to comments on “Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016”

Elise Deluche; Alison Antoine; Thomas Bachelot; Mathieu Robain; David Perol; Suzette Delaloge

doi:10.1016/j.ejca.2020.09.005

A response letter to comments on “Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016”

Elise Deluche, Alison Antoine, Thomas Bachelot, Mathieu Robain, David Perol, Suzette Delaloge

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

2 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	165-166
Nombre de pages	2
journal	European Journal of Cancer
Volume	140
Les DOIs	https://doi.org/10.1016/j.ejca.2020.09.005
état	Publié - 1 nov. 2020

Accès au document

10.1016/j.ejca.2020.09.005

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{483864798af34e78949425a39ec6dd02,

title = "A response letter to comments on “Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016”",

author = "Elise Deluche and Alison Antoine and Thomas Bachelot and Mathieu Robain and David Perol and Suzette Delaloge",

note = "Funding Information: S.D . reports institutional fees and non-financial support from Roche / Genentech ; grants, institutional fees and non-financial support from Pfizer ; institutional fees and non-financial support from Puma ; grants, institutional fees and non-financial support from AstraZeneca ; grants, institutional fees and non-financial support from Novartis ; and institutional fees and non-financial support from Amgen . Funding Information: The ESME MBC database receives financial support from an industrial consortium (Roche, Pfizer, AstraZeneca, MSD, Eisai and Daiichi Sankyo). Data collection, analysis and publication is managed entirely by R&D UNICANCER independently of the industrial consortium.S.D. reports institutional fees and non-financial support from Roche / Genentech; grants, institutional fees and non-financial support from Pfizer; institutional fees and non-financial support from Puma; grants, institutional fees and non-financial support from AstraZeneca; grants, institutional fees and non-financial support from Novartis; and institutional fees and non-financial support from Amgen.T.B. reports grants, personal fees and non-financial support from Novartis, Pfizer, AstraZeneca; personal fees from Seattle Genetics; and personal fees and non-financial support from Roche.D.P. reports personal fees from ROCHE, personal fees and non-financial support from AstraZeneca, and grants from MSD, outside the submitted work. Funding Information: The ESME MBC database receives financial support from an industrial consortium ( Roche , Pfizer , AstraZeneca , MSD , Eisai and Daiichi Sankyo ). Data collection, analysis and publication is managed entirely by R&D UNICANCER independently of the industrial consortium. ",

year = "2020",

month = nov,

day = "1",

doi = "10.1016/j.ejca.2020.09.005",

language = "English",

volume = "140",

pages = "165--166",

journal = "European Journal of Cancer",

issn = "0959-8049",

}

TY - JOUR

T1 - A response letter to comments on “Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016”

AU - Deluche, Elise

AU - Antoine, Alison

AU - Bachelot, Thomas

AU - Robain, Mathieu

AU - Perol, David

AU - Delaloge, Suzette

N1 - Funding Information: S.D . reports institutional fees and non-financial support from Roche / Genentech ; grants, institutional fees and non-financial support from Pfizer ; institutional fees and non-financial support from Puma ; grants, institutional fees and non-financial support from AstraZeneca ; grants, institutional fees and non-financial support from Novartis ; and institutional fees and non-financial support from Amgen . Funding Information: The ESME MBC database receives financial support from an industrial consortium (Roche, Pfizer, AstraZeneca, MSD, Eisai and Daiichi Sankyo). Data collection, analysis and publication is managed entirely by R&D UNICANCER independently of the industrial consortium.S.D. reports institutional fees and non-financial support from Roche / Genentech; grants, institutional fees and non-financial support from Pfizer; institutional fees and non-financial support from Puma; grants, institutional fees and non-financial support from AstraZeneca; grants, institutional fees and non-financial support from Novartis; and institutional fees and non-financial support from Amgen.T.B. reports grants, personal fees and non-financial support from Novartis, Pfizer, AstraZeneca; personal fees from Seattle Genetics; and personal fees and non-financial support from Roche.D.P. reports personal fees from ROCHE, personal fees and non-financial support from AstraZeneca, and grants from MSD, outside the submitted work. Funding Information: The ESME MBC database receives financial support from an industrial consortium ( Roche , Pfizer , AstraZeneca , MSD , Eisai and Daiichi Sankyo ). Data collection, analysis and publication is managed entirely by R&D UNICANCER independently of the industrial consortium.

PY - 2020/11/1

Y1 - 2020/11/1

UR - http://www.scopus.com/inward/record.url?scp=85092628324&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2020.09.005

DO - 10.1016/j.ejca.2020.09.005

M3 - Letter

C2 - 33020000

AN - SCOPUS:85092628324

SN - 0959-8049

VL - 140

SP - 165

EP - 166

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -